School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
Guy's and St Thomas' Hospital, London, UK.
Pacing Clin Electrophysiol. 2020 Sep;43(9):966-973. doi: 10.1111/pace.13926. Epub 2020 May 9.
Endocardial pacing may be beneficial in patients who fail to improve following conventional epicardial cardiac resynchronization therapy (CRT). The potential to pace anywhere inside the left ventricle thus avoiding myocardial scar and targeting the latest activating segments may be particularly important. The WiSE-CRT system (EBR systems, Sunnyvale, CA) reliably produces wireless, endocardial left ventricular (LV) pacing. The purpose of this analysis was to determine whether this system improved symptoms or led to LV remodeling in patients who were nonresponders to conventional CRT.
An international, multicenter registry of patients who were nonresponders to conventional CRT and underwent implantation with the WiSE-CRT system was collected.
Twenty-two patients were included; 20 patients underwent successful implantation with confirmation of endocardial biventricular pacing and in 2 patients, there was a failure of electrode capture. Eighteen patients proceeded to 6-month follow-up; endocardial pacing resulted in a significant reduction in QRS duration compared with intrinsic QRS duration (26.6 ± 24.4 ms; P = .002) and improvement in left ventricular ejection fraction (LVEF) (4.7 ± 7.9%; P = .021). The mean reduction in left ventricular end-diastolic volume was 8.3 ± 42.3 cm (P = .458) and left ventricular end-systolic volume (LVESV) was 13.1 ± 44.3 cm (P = .271), which were statistically nonsignificant. Overall, 55.6% of patients had improvement in their clinical composite score and 66.7% had a reduction in LVESV ≥15% and/or absolute improvement in LVEF ≥5%.
Nonresponders to conventional CRT have few remaining treatment options. We have shown in this high-risk patient group that the WiSE-CRT system results in improvement in their clinical composite scores and leads to LV remodeling.
对于那些在常规心外膜心脏再同步治疗(CRT)后未能改善的患者,心内膜起搏可能是有益的。因此,能够在左心室内部的任何地方起搏,从而避免心肌瘢痕并针对最新的激活节段起搏,可能尤为重要。WiSE-CRT 系统(EBR 系统,加利福尼亚州森尼韦尔)可靠地产生无线心内膜左心室(LV)起搏。本分析的目的是确定该系统是否能改善对常规 CRT 无反应的患者的症状或导致 LV 重构。
收集了对常规 CRT 无反应并接受 WiSE-CRT 系统植入的国际多中心患者注册。
共纳入 22 例患者;20 例患者成功植入并确认了心内膜双心室起搏,2 例患者电极捕获失败。18 例患者进行了 6 个月的随访;与固有 QRS 持续时间相比,心内膜起搏导致 QRS 持续时间显著缩短(26.6 ± 24.4 ms;P =.002),左心室射血分数(LVEF)改善(4.7 ± 7.9%;P =.021)。左心室舒张末期容积的平均减少为 8.3 ± 42.3 cm(P =.458),左心室收缩末期容积(LVESV)减少 13.1 ± 44.3 cm(P =.271),均无统计学意义。总体而言,55.6%的患者临床综合评分改善,66.7%的患者 LVESV 减少≥15%和/或 LVEF 绝对改善≥5%。
对常规 CRT 无反应的患者治疗选择有限。我们在这一高危患者群体中表明,WiSE-CRT 系统可改善其临床综合评分,并导致 LV 重构。